Sientra jumps on return to U.S. market

Sientra (NSDQ:SIEN) shares jumped today after the breast implant maker said all of its products are slated to go back on the U.S. market March 1, 4 months after Brazilian regulators shut down production at its sole supplier. Santa Barbara, Calif.-based Sientra, which tapped new CEO Jeffrey Nugent shortly after Brazilian regulator Anvisa last October suspended production at Silimed, Sientra’s supplier, and the U.K.’s Medicines & Healthcare Products Regulatory Agency halted sales. SIEN share prices hit a 52-week low on the news, but clawed back some of their value last month after Nugent said independent testing found the implants safe. Today the company said that, based on the worst-case tests in which its implants showed a high safety margin “compared to numerous U.S. and international standards, it would look to get back on the U.S. market. Sientra, Inc. (NASDAQ:SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced all of its medical devices, including all Sientra breast implant products, will return to the U.S. market beginning March 1, 2016. “We are extremely pleased to return our products to the U.S. market where we can once again provide choice to board-certified plastic surgeons. Our decision to place the voluntary hold on Sientra products was difficult, but we felt it was the responsible action to take at the time amid the speculation, to ensure that Sientra products remain a safe choi...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cosmetic/Aesthetic Wall Street Beat Women's Health Sientra Source Type: news